Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
REVELUTION post hoc QoL: relugolix vs leuprolide with RT, 12-mo IPSS 5.66 vs 9.22 (p=0.039), EPIC-CP total 12.25 vs 17.25 (p=0.02).
Prostate carried the day: a post hoc QoL analysis (N=65) of REVELUTION in localized intermediate- or high-risk PCa favored oral relugolix over leuprolide alongside RT on urinary and total EPIC-CP scores. Higher 12-mo testosterone with relugolix confounds the read, and RT dose, fractionation, and target volume were not reported.
read the full digest →Studies · 140
- REVELUTIONPost hoc QoL: relugolix vs leuprolide with RT gave lower 12-mo IPSS (5.66 vs 9.22, p=0.039) and EPIC-CP total (12.25 vs 17.25, p=0.02).
- SWOG S1827/MAVERICKMRI surveillance alone beat MRI + PCI for cognitive failure-free survival, HR 0.60 (90% CI 0.46-0.78), in LS- and ES-SCLC without brain mets after first-line therapy.
- PACE-A≥1 urinary pad 14/29 (48%) RP vs 3/36 (8%) SBRT; BCF HR 0.48 (95% CI 0.16-1.46), mFU 8 yrs, GG1-2 localised PCa.
- STOP3-yr biochemical progression 21% vs 60% (p=0.004) adding SBRT to intermittent ADT in PSMA PET-detected, conventional-imaging-negative oligometastatic HSPC/BCR.
- ROADSCs-131 tile brachytherapy at resection cut surgical bed recurrence vs post-op SRT: time-to-SBR HR 0.06 (0.01-0.46), SB-RFS HR 0.48, in newly diagnosed resected brain mets.
- LAVA-CRLM1-yr freedom from local progression 83.0% SBRT vs 77.7% MWA (HR 0.87, p=0.70); treatment-related G2+ toxicity 3% vs 25% in oligometastatic CRLM.
- ROAM/EORTC-1308Adjuvant IMRT 60 Gy/30 fx vs observation after complete resection of WHO grade 2 atypical meningioma: DFS HR 0.51 (0.27–0.97); 5-yr DFS 79.9% vs 64.3%.
- BIG 3-07/TROG 07.01Tumour bed boost after WBI in resected non-low-risk DCIS: 5-yr freedom from LR 97.1% vs 92.7%, HR 0.47 (0.31-0.72), p<0.001.
- Testosterone Treatment in Prostate Cancer Survivors (Bhasin RCT)Sexual activity +0.91 daily events vs placebo (95% CI 0.56-1.26, P<.001), zero biochemical recurrences, 12wk TRT in hypogonadal men post-RP for Gleason 3+3/3+4.
- ASTRO Clinical Practice Guideline: RT for Bladder CancerTMT recommended (strong, high QoE) as alternative to RC for select cT2-4aN0M0 MIBC; bladder-alone 5500 cGy/20 fx or 6400-6480 cGy/32-36 fx.
- Gamma Knife vs LINAC-based radiosurgery for vestibular schwannoma (retrospective review)Local control 98.8%; no difference in new vertigo, gait disturbance or facial palsy with GKRS (n=36) vs LINAC (n=49) SRS for vestibular schwannoma.
- SWOG S1827/MAVERICKRandomized phase III, LS or ES SCLC: PCI 25 Gy/10 fx + MRI vs MRI surveillance alone; no CFFS or OS results in source tweets.